On 16 March 2023 LYO-X attended the BEAM Alliance General Assembly in Basel, Switzerland.
BEAM Alliance represents over 70 SMEs that develop solutions to fight antimicrobial resistance (AMR). AMR refers to the growing resistance of pathogens, such as bacteria, to antimicrobials. This process has been exacerbated by the overuse and misuse of antimicrobials. As such, AMR undermines our ability to treat or prevent infections commonly associated with surgeries, transplants or chemotherapy.
LYO-X supports this important initiative as an associated organization. Dr. Jannik Vollmer, Senior Modeler at LYO-X, points out that the "silent" pandemic needs to be fought now.
LYO-X can support the initiative by providing modelling expertise to SMEs in the pre-clinical and clinical stage, such as establishing breakpoints or calculation of probability of target attainment. LYO-X is using PK/PD and mechanistic modelling of bacterial killing to help define the effective dose early on and evaluate how it fits into the therapeutic window. This ensures that promising drug candidates can advance into the clinic with the right dose that is effective and safe and that compounds that do not have a therapeutic margin are deprioritized.